Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Koestenberger, M; Hansmann, G.
Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
PULM CIRC. 2018; 8(3): UNSP 2045894018793580 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Köstenberger Martin
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.

Find related publications in this database (Keywords)
Pediatric
prostacyclin receptor agonist
pulmonary arterial hypertension
selexipag
© Meduni Graz Impressum